0001193125-25-060850.txt : 20250324 0001193125-25-060850.hdr.sgml : 20250324 20250324070121 ACCESSION NUMBER: 0001193125-25-060850 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20250324 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250324 DATE AS OF CHANGE: 20250324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DBV Technologies S.A. CENTRAL INDEX KEY: 0001613780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36697 FILM NUMBER: 25762194 BUSINESS ADDRESS: STREET 1: 107 AVENUE DE LA REPUBLIQUE CITY: CHATILLON STATE: I0 ZIP: 92320 BUSINESS PHONE: 33(0)155427878 MAIL ADDRESS: STREET 1: 107 AVENUE DE LA REPUBLIQUE CITY: CHATILLON STATE: I0 ZIP: 92320 8-K 1 d932759d8k.htm 8-K 8-K
00-0000000 true 0001613780 false 0001613780 2025-03-24 2025-03-24 0001613780 us-gaap:CommonStockMember 2025-03-24 2025-03-24 0001613780 dei:AdrMember 2025-03-24 2025-03-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

March 24, 2025

Date of Report (Date of earliest event reported)

 

 

DBV Technologies S.A.

(Exact name of registrant as specified in its charter)

 

 

 

France   001-36697   Not applicable

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

107 avenue de la République

92320 Châtillon France

   Not Applicable
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: +33 1 55 42 78 78

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Ordinary shares, nominal value €0.10 per share   n/a   The Nasdaq Stock Market LLC *
American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share   DBVT   The Nasdaq Stock Market LLC

 

*

Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02.

Results of Operations and Financial Condition

On March 24, 2025, DBV Technologies S.A. (the “Company”) issued a press release announcing preliminary unaudited financial results for the fiscal year ended December 31, 2024. These amounts are unaudited and preliminary, are subject to completion of financial closing procedures that could result in changes to the amounts, and do not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 8.01.

Other Events

On March 24, 2025, the Company issued the Press Release. The sections of the Press Release below the headings “FDA Update” and “Forward Looking Statements” are incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit

No.

    Description
99.1    Press Release issued March 24, 2025
104    Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 24, 2025     DBV TECHNOLOGIES S.A.
    By:  

/s/ Virginie Boucinha

    Name:   Virginie Boucinha
    Title:   Chief Financial Officer
 EX-99.1 2 d932759dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results1

 

  •  

COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required

 

  •  

FDA confirms safety exposure data generated from VITESSE Phase 3 clinical study and VITESSE Open-Label Extension (OLE) are sufficient to support a Biologics License Application (BLA) for Viaskin peanut patch in children 4 – 7-years-old

 

  •  

VITESSE topline results on-track for the fourth quarter of 2025

 

  •  

BLA submission for Viaskin peanut patch in children 4 – 7-years-old is now expected in the first half of 2026; DBV anticipates this path may accelerate potential launch, if approved by the FDA, by approximately one year

 

  •  

DBV also reports unaudited financial results1 for the full year 2024, including cash and cash equivalents

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT, the “Company”), a clinical-stage biopharmaceutical company, today announced that in a Written Responses Only to the Company’s Type D IND meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a Biologics License Application (BLA) filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required, which accelerates the timeline for a BLA submission of Viaskin® peanut patch in 4 – 7-year-olds with a peanut allergy. The Company also reported unaudited financial results1 for the full year 2024, including cash and cash equivalents.

 

1 

The financial information published in this press release shall be considered as “données financières estimées” or “estimated financial data”, according to AMF Position-Recommendation DOC-2016-05.

LOGO

 

FDA Update

Based on the Written Responses Only received, DBV will no longer conduct the COMFORT Children 6-month supplemental safety study. The Company will utilize the safety data from the VITESSE participants randomized to active treatment as well as placebo-crossover participants in the VITESSE Open Label Extension (OLE), expediting the BLA submission for the Viaskin peanut patch from the previously anticipated timeline. Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.

“DBV’s alignment with FDA represents a tremendous achievement for food allergy families, clinicians, researchers, and countless external partners that have been working for many years to advance the Viaskin peanut patch in children living with peanut allergy,” said Daniel Tassé, Chief Executive Officer, DBV Technologies. “I thank the FDA and the Review Team for their collaboration and constructive approach during the Type D meeting process, which enabled us to gain clarity expeditiously. DBV is commencing preparations for a BLA submission in the first half of 2026 to be supported by the Phase 3 VITESSE study, which is on-track for readout of topline results in the fourth quarter of 2025. We believe that the Viaskin peanut patch has the potential to change the lives of millions of children living with peanut allergy. This mission drives DBV every day. We will continue to work hard to bring this innovative treatment option to market.”

FDA has agreed with DBV’s proposal to support potential licensure of the Viaskin peanut patch in children 4 – 7-years-old with the efficacy, safety and patch wear time data generated from VITESSE, which enrolled 654 participants, making it the largest Phase 3 clinical trial for peanut allergy ever conducted in this age group. This will include safety data from study participants on active treatment for 12-months and the additional crossover study participants on active treatment in the VITESSE OLE. At the time of BLA submission, the safety database will be comprised of more than 500 study participants on Viaskin peanut patch active treatment.

LOGO

 

“I am extremely pleased to see that FDA agrees that the VITESSE safety exposure data being generated is sufficiently robust to support a BLA in this age group,” said Dr. David Fleischer, FAAAAI, FACAAI, Global Principal Investigator, VITESSE, Professor of Pediatrics at Children’s Hospital Colorado. “This is the largest, most rigorous study ever conducted in peanut allergic children between 4 and 7 years of age. The insights that we will gain from this work are invaluable to the disease space as a whole. Clinicians want to see additional FDA approved treatment options in food allergy so that we may conduct thoughtful conversations with our patients about which option is best for them and their lifestyle. I look forward to the day when the Viaskin peanut patch may be part of those conversations.”

As previously communicated, DBV also plans to pursue an Accelerated Approval pathway for the Viaskin peanut patch in toddlers 1 – 3-years-old with a peanut allergy. The COMFORT Toddlers 6-month supplemental safety study is on-track to initiate in the second quarter of 2025 and will recruit approximately 480 study participants. The BLA submission for the 1 – 3-year-old indication is expected in the second half of 2026, subject to the successful completion of the COMFORT Toddlers study.

“On behalf of our 6,500 members in the United States and globally, we are pleased to support potential new innovations in food allergy, including the Viaskin peanut patch, that could add to the toolbox allergist-immunologists consider when treating patients,” said Dr. James Tracy, DO, FACAAI, President, American College of Allergy, Asthma, and Immunology (ACAAI). “The ACAAI advocates for the best treatment outcomes for our patients under the care of their clinician. We are encouraged by the robust dataset being generated by the VITESSE Phase 3 study, in which many of our members are currently serving as investigators. We continue to support DBV’s development of the Viaskin peanut program in this 4 – 7-year-old age group. Our community encourages as many treatment options as possible to reach those who are eagerly awaiting.”

Unaudited Financial Results1 for Full Year 2024

These unaudited financial results1 have been examined by the Board of Directors of the Company on March 23, 2025, and the audited final financial statements are expected to be approved by the Board of Directors on March 28, 2025.

The audit procedures by the statutory auditors of the Company on the 2024 consolidated full year financial statements are in progress.

LOGO

 

Financial results are presented under both U.S. generally accepted accounting principles (“US GAAP”) and the International Financial Reporting Standards (“IFRS”) as adopted by the European Union. Financial statement comments refer to U.S. GAAP financial statements. Differences between US GAAP and IFRS as adopted by the European Union consolidated financial statements result mainly from the discrepancies arising from the application of lease accounting standards.

In order to finance its activities, the Company needs to raise additional funds and is actively reviewing potential financing and strategic options with its financial advisors.

Cash and Cash Equivalents

Cash and cash equivalents amounted to $32.5 million as of December 31, 2024, compared to $141.4 million as of December 31, 2023, a net cash consumption of $108.9 million, mainly driven by external clinical trial-related expenses, in particular those related to subject enrollment in the Company’s ongoing VITESSE Phase 3 clinical trial, with topline results expected by the fourth quarter of 2025 as previously communicated, as well as regulatory and manufacturing activities to support ongoing clinical trials.

The Company has incurred operating losses and negative cash flows from operations since inception. As of the date of this press release, the Company’s available cash and cash equivalents will not be sufficient to support its operating plan for the next 12 months. Based on its current operations, plans and assumptions, the Company expects that its cash and cash equivalents will be sufficient to fund its operations only into April 2025.

As such, there is substantial doubt regarding its ability to continue as a going concern.

The Company intends to seek additional capital as it continues research and development efforts and prepares for the filing of the BLA and launch of Viaskin® Peanut patch, if approved.

The Company cannot guarantee that it will successfully obtain the necessary financing to meet its needs or to obtain funds at attractive terms and conditions. If the Company is not successful in its financing objectives, the Company could have to scale back its operations, notably by delaying or reducing the scope of its research and development efforts or obtain financing through arrangements with collaborators or others that may require the Company to relinquish rights to its product candidates that the Company might otherwise seek to develop or commercialize independently or discontinue all or part of its operations.

LOGO

 

     U.S. GAAP      IFRS  
     Year ended      Year ended  
In millions of USD    December 31,      December 31,  

(unaudited)    

    2024      2023      2024      2023  

Net cash & cash equivalents at the beginning of the period

      141.4        209.2        141.4        209.2  

Net cash flow used in operating activities

      (104.5 )       (79.7 )       (102.7 )       (77.6 ) 

Net cash flow provided by / (used in) investing activities

      (0.8 )       (0.8 )       (0.6 )       (0.8 ) 

Net cash flow provided by / (used in) financing activities

      0.6        6.8        (0.7 )       4.8  

Effect of exchange rate changes on cash & cash equivalents

      (4.3 )       5.9        (5.3 )       5.9  

Net cash & cash equivalents at the end of the period

      32.5        141.4        32.1        141.4  
  

 

 

     

 

 

     

 

 

     

 

 

  

Operating Income

Operating income amounted to $4.2 million for the year ended December 31, 2024, compared with $15.7 million for the same period in 2023. This decrease by $11.5 million is composed of (1) $7.0 million following the mutual termination of the Development, Collaboration, and License Agreement with with Societé des Produits Nestlé S.A (formerly NESTEC S.A.) (“NESTEC”), and (2) a lower Research Tax Credit (“CIR”). This decrease is due to a corrective CIR filed in 2023 by the Company for $2.9 million for fiscal years 2020, 2021 and 2022 and a greater proportion of study activities carried out in North America in 2024 as compared to 2023, which are not eligible to the CIR.

 

     U.S. GAAP      IFRS  
     Year ended      Year ended  
In millions of USD    December 31,      December 31,  

(unaudited)    

    2024      2023      2024      2023  

Research tax credits

      4.1        8.8        4.1        8.8  

Other operating income

      0.0        7.0        0.0        7.0  

Operating income

      4.2        15.7        4.2        15.7  
  

 

 

     

 

 

     

 

 

     

 

 

  

Operating Expenses

Operating expenses amounted to $120.7 million for the year ended December 31, 2024, compared with $92.2 million for the year ended December 31, 2023, an increase of $28.5 million. This increase is primarily driven by research & development costs of $29.1 million resulting from (1) subject enrollment in the Company’s ongoing VITESSE Phase 3 clinical trial, (2) preparatory activities for the Company’s COMFORT supplemental safety studies in anticipation of initiation after FDA alignment, and (3) regulatory and manufacturing activities to support ongoing clinical trials.

LOGO

 

General and administrative expenses decreased by $0.8 million during the year ended December 31, 2024, compared to the year ended December 31, 2023, primarily due to the positive impact of office moves in France and the U.S.

 

     U.S. GAAP      IFRS  
     Year ended      Year ended  
In millions of USD    December 31,      December 31,  

(unaudited)   

    2024      2023      2024      2023  

Research & Development

      (89.3 )       (60.2 )       (89.2 )       (60.1 ) 

Sales & Marketing

      (2.7 )       (2.4 )       (2.7 )       (2.4 ) 

General & Administrative

      (28.7 )       (29.5 )       (28.8 )       (29.5 ) 

Operating expenses

      (120.7 )       (92.2 )       (120.6 )       (92.0 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Net Loss Per Share

The Company recorded a net loss of $113.9 million for the year ended December 31, 2024, compared to a net loss of $72.7 million for the year ended December 31, 2023.

On a per share basis, net loss (based on the weighted average number of shares outstanding over the period) was $(1.17) for the year ended December 31, 2024.

 

     U.S. GAAP      IFRS  
     Year ended      Year ended  
     December 31,      December 31,  

(unaudited)

    2024      2023      2024      2023  

Net income / (loss) (in millions of USD)

      (113.9 )       (72.7 )       (114.1 )       (72.7 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

Basic / diluted net income / (loss) per share (USD/share)

      (1.17 )       (0.76 )       (1.18 )       (0.76 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

LOGO

 

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited)

 

     U.S. GAAP      IFRS  
     Year ended      Year ended  
In millions of USD    December 31,      December 31,  

(unaudited)    

    2024      2023      2024      2023  

Assets

      65.7        183.0        65.5        183.0  

of which cash & cash equivalents

      32.5        141.4        32.5        141.4  

Liabilities

      38.3        42.8        38.2        42.7  

Shareholders’ equity

      27.4        140.2        27.4        140.3  
  

 

 

     

 

 

     

 

 

     

 

 

  

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

 

     U.S. GAAP     IFRS  
     Year ended     Year ended  
In millions of USD    December 31,     December 31,  

(unaudited)    

    2024     2023     2024     2023  

Operating income

      4.2       15.7       4.2       15.7  

Research & Development

      (89.3 )      (60.2 )      (89.2 )      (60.1 ) 

Sales & Marketing

      (2.7 )      (2.4 )      (2.7 )      (2.4 ) 

General & Administrative

      (28.7 )      (29.5 )      (28.8 )      (29.5 ) 

Operating expenses

      (120.7 )      (92.2 )      (120.6 )      (92.0 ) 

Financial income/(expenses)

      2.7       3.7       2.4       3.6  

Income tax

      (0.1 )      (0.0 )      (0.1 )      (0.0 ) 

Net loss

      (113.9 )      (72.7 )      (114.1 )      (72.7 ) 

Basic/diluted net loss per share attributable to shareholders

      (1.17 )      (0.76 )      (1.18 )      (0.76 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

 

     U.S. GAAP     IFRS  
     Year ended     Year ended  
In millions of USD    December 31,     December 31,  

(unaudited)    

    2024     2023     2024     2023  

Net cash flows provided / (used) in operating activities

      (104.5 )      (79.7 )      (102.7 )      (77.6 ) 

Net cash flows provided / (used) in investing activities

      (0.8 )      (0.8 )      (0.6 )      (0.8 ) 

Net cash flows provided / (used) in financing activities

      0.6       6.8       (0.7 )      4.8  

Effect of exchange rate changes on cash & cash equivalents

         

(U.S. GAAP presentation)

      (4.3 )      5.9       (5.3 )      5.9  

Net increase / (decrease) in cash & cash equivalents

      (108.9 )      (67.8 )      (109.3 )      (67.8 ) 

Net cash & cash equivalents at the beginning of the period

      141.4       209.2       141.4       209.2  

Net cash & cash equivalents at the end of the period

      32.5       141.4       32.1       141.4  
  

 

 

    

 

 

    

 

 

    

 

 

  

LOGO

 

Disclaimer

The unaudited financial results as of and for the year ended December 31, 2024 included in

this press release have been examined by the Board of Directors of the Company on March 23, 2025 and remain subject to any adjustments, and other developments arising between now and the time such financial results are finalized. The Company’s independent auditors have not yet audited nor have they expressed any opinion or any other form of assurance on these unaudited financial results, in particular DBV has not yet obtained assurance from its auditors that the financial statements will be certified without qualification. The audit procedures by the statutory auditors of the Company are in progress.

About DBV Technologies

DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

Forward Looking Statements

This press release may contain forward-looking statements and estimates, including statements regarding the Company’s financial condition, forecast of its cash runway, financing plans, the therapeutic potential of VIASKIN® Peanut patch and EPIT™, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations

LOGO

 

regarding initiation of the confirmatory study, plans and expectations with respect to the submission of BLAs to FDA, anticipated support for the BLA submission, and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the Company’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include DBV’s ability to obtain necessary financing, uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the Company’s ability to successfully execute on its budget discipline measures. The review of potential financial and strategic options may not result in any particular action or transaction being pursued, entered into or consummated, and there is no assurance as to the timing, sequence or outcome of any action or transaction or series of actions or transactions. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on its financial statements, and it is likely that investors will lose all or part of their investment. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), the Company’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including future filings and reports made with the AMF and SEC by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, the Company undertakes no obligation to update or revise the information contained in this press release.

Viaskin is a registered trademark and EPIT is a trademark of DBV Technologies.

Investor Contact

Katie Matthews

DBV Technologies

katie.matthews@dbv-technologies.com

Media Contact

Angela Marcucci

DBV Technologies

angela.marcucci@dbv-technologies.com

EX-101.SCH 3 dbvt-20250324.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 dbvt-20250324_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 dbvt-20250324_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Document Information [Table] Document Information [Table] Document Information [Line Items] Document Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] ADR [Member] American Depositary Share [Member] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 1 Entity Address Postal Zip Code Entity Address Postal Zip Code Entity Address City Or Town Entity Address City Or Town Entity Address Country Entity Address Country Country Region Country Region City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title No Trading Symbol Flag No Trading Symbol Flag Security Exchange Name Security Exchange Name Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 6 dbvt-20250324_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g932759g0324055702146.jpg GRAPHIC begin 644 g932759g0324055702146.jpg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end GRAPHIC 8 g932759g24c68.jpg GRAPHIC begin 644 g932759g24c68.jpg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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information
Mar. 24, 2025
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Mar. 24, 2025
Entity Registrant Name DBV Technologies S.A.
Entity Incorporation State Country Code I0
Entity File Number 001-36697
Entity Tax Identification Number 00-0000000
Entity Address Address Line 1 107 avenue de la République
Entity Address Postal Zip Code 92320
Entity Address City Or Town Châtillon
Entity Address Country FR
Country Region 33
City Area Code 1
Local Phone Number 55 42 78 78
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001613780
Amendment Flag false
Common Stock [Member]  
Document Information [Line Items]  
Security 12b Title Ordinary shares, nominal value €0.10 per share
No Trading Symbol Flag true
Security Exchange Name NASDAQ
American Depositary Share [Member]  
Document Information [Line Items]  
Security 12b Title American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share
Security Exchange Name NASDAQ
Trading Symbol DBVT
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

%H<.&7J/P$ #P" / " M 1<1 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " J.'A:)!Z;HJT #X M 0 &@ @ &#$@ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E M;'-02P$"% ,4 " J.'A:99!YDAD! #/ P $P @ %H L$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" "R% ! end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 3 24 1 false 2 0 false 0 false false R1.htm 000001 - Document - Document and Entity Information Sheet http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d932759d8k.htm dbvt-20250324.xsd dbvt-20250324_def.xml dbvt-20250324_lab.xml dbvt-20250324_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d932759d8k.htm": { "nsprefix": "dbvt", "nsuri": "http://www.dbv-technologies.com/20250324", "dts": { "inline": { "local": [ "d932759d8k.htm" ] }, "schema": { "local": [ "dbvt-20250324.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "dbvt-20250324_def.xml" ] }, "labelLink": { "local": [ "dbvt-20250324_lab.xml" ] }, "presentationLink": { "local": [ "dbvt-20250324_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 31, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 26 }, "report": { "R1": { "role": "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "000001 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2025-03-24_to_2025-03-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d932759d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2025-03-24_to_2025-03-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d932759d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AdrMember", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ADR [Member]", "terseLabel": "American Depositary Share [Member]", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r6" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Country Region", "terseLabel": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "terseLabel": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "terseLabel": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "terseLabel": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Country", "terseLabel": "Entity Address Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "terseLabel": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.dbv-technologies.com//20250324/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r7" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001193125-25-060850-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-25-060850-xbrl.zip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end XML 19 d932759d8k_htm.xml IDEA: XBRL DOCUMENT 0001613780 2025-03-24 2025-03-24 0001613780 us-gaap:CommonStockMember 2025-03-24 2025-03-24 0001613780 dei:AdrMember 2025-03-24 2025-03-24 00-0000000 true 0001613780 false 8-K 2025-03-24 DBV Technologies S.A. I0 001-36697 107 avenue de la République 92320 Châtillon FR 33 1 55 42 78 78 false false false false Ordinary shares, nominal value €0.10 per share NASDAQ American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share DBVT NASDAQ false